Alimera Sciences, Inc.

ALIM

US0162592028

Pharmaceuticals

Delayed Nasdaq Other stock markets 20:36:56 10/05/2024 BST			5-day change	1st Jan Change
3.53 ^USD	+4.44%		-3.70%	-18.63%

03-25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT
03-19	Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	CI

Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 07, 2024 at 12:30 pm

Alimera Sciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 80.75 million compared to USD 54.13 million a year ago. Net loss was USD 20.13 million compared to USD 18.11 million a year ago.

Latest news about Alimera Sciences, Inc.

Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	03-25	MT
Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	03-19	CI
Transcript : Alimera Sciences, Inc., Q4 2023 Earnings Call, Mar 07, 2024	03-07
Alimera Sciences, Inc. Enters into the Seventh Amendment to Its Loan and Security Agreement	03-07	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	03-07	MT
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	03-07	MT
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	03-07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07	CI
North American Morning Briefing : Powell Still in -2-	03-07	DJ
Alimera Completes Recruitment for the Synchronicity Study	01-04	CI
Alimera Sciences Appoints New CFO	01-02	MT
Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer	01-02	CI
Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations	12-12	CI
Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors	11-08	CI
Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology	31/10/23	CI
Transcript : Alimera Sciences, Inc., Q3 2023 Earnings Call, Oct 26, 2023	26/10/23
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q3 Revenue $23.4M	26/10/23	MT
Alimera Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
Alimera Sciences Names Jason Werner as COO	03/10/23	MT
Alimera Sciences, Inc. Announces Management Appointments	03/10/23	CI
Transcript : Alimera Sciences, Inc., Q2 2023 Earnings Call, Aug 10, 2023	10/08/23
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q2 Revenue $17.5M	10/08/23	MT
Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
North American Morning Briefing : Attention Turns -2-	10/08/23	DJ

Chart Alimera Sciences, Inc.

Duration

Period

More charts

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.

Sector

Pharmaceuticals

Calendar

13/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alimera Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.38 USD

Average target price

8 USD

Spread / Average Target

+136.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ALIMERA SCIENCES, INC.	-18.63%	177M
CSL LIMITED	-2.61%	88.47B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.71B
BIOGEN INC.	-13.92%	32.43B
UCB	+55.89%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-16.00%	15.52B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	12.17B
INCYTE CORPORATION	-15.40%	12.01B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	12B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	8.87B

Biopharmaceuticals